Enhanced plasma ghrelin levels in patients with functional dyspepsia

T. Nishizawa, Hidekazu Suzuki, Y. Nomoto, Tatsuhiro Masaoka, H. Hosoda, M. Mori, T. Ohara, T. Morishita, K. Kangawa, T. Hibi

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Ghrelin, growth-hormone-releasing peptide, has been reported to accelerate food intake and gastrointestinal motility. Aim: The present study was designed to investigate the plasma ghrelin levels in patients with functional dyspepsia (FD). Patients and Methods: Ninety-seven patients, who showed no evidence of peptic ulcer disease or gastrointestinal cancer on upper gastrointestinal endoscopy, were recruited. Seventeen patients who had no gastrointestinal symptoms were recruited as controls. Forty-seven patients were diagnosed to be suffering from FD, based on the Rome II criteria. The FD patients were further subdivided into those with ulcer-like FD, dysmotility-like FD and non-specific-type FD, based on their Gastrointestinal Symptom Rating Scale (GSRS) scores. Fourteen patients were categorized as having gastro-oesophageal reflux disease, and 19 patients were excluded as having the irritable bowel syndrome, based on the GSRS. The plasma ghrelin levels were measured by radioimmunoassay. Results: The plasma ghrelin levels were significantly higher in FD patients, especially in those with dysmotility-like FD, as compared with those in controls. The plasma ghrelin levels were also correlated well with the indigestion scores. Conclusion: Plasma ghrelin levels are significantly higher in patients with dysmotility-like FD, suggesting that this parameter could become useful as a novel supportive marker for the diagnosis of FD.

Original languageEnglish
Pages (from-to)104-110
Number of pages7
JournalAlimentary Pharmacology and Therapeutics Symposium Series
Volume2
Issue number1
DOIs
Publication statusPublished - 2006 Jul

Fingerprint

Ghrelin
Dyspepsia
Esophageal Diseases
Gastrointestinal Motility
Gastrointestinal Neoplasms
Gastrointestinal Endoscopy
Irritable Bowel Syndrome
Gastroesophageal Reflux
Peptic Ulcer
Ulcer
Radioimmunoassay
Eating

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Enhanced plasma ghrelin levels in patients with functional dyspepsia. / Nishizawa, T.; Suzuki, Hidekazu; Nomoto, Y.; Masaoka, Tatsuhiro; Hosoda, H.; Mori, M.; Ohara, T.; Morishita, T.; Kangawa, K.; Hibi, T.

In: Alimentary Pharmacology and Therapeutics Symposium Series, Vol. 2, No. 1, 07.2006, p. 104-110.

Research output: Contribution to journalArticle

Nishizawa, T, Suzuki, H, Nomoto, Y, Masaoka, T, Hosoda, H, Mori, M, Ohara, T, Morishita, T, Kangawa, K & Hibi, T 2006, 'Enhanced plasma ghrelin levels in patients with functional dyspepsia', Alimentary Pharmacology and Therapeutics Symposium Series, vol. 2, no. 1, pp. 104-110. https://doi.org/10.1111/j.1746-6342.2006.00032.x
Nishizawa, T. ; Suzuki, Hidekazu ; Nomoto, Y. ; Masaoka, Tatsuhiro ; Hosoda, H. ; Mori, M. ; Ohara, T. ; Morishita, T. ; Kangawa, K. ; Hibi, T. / Enhanced plasma ghrelin levels in patients with functional dyspepsia. In: Alimentary Pharmacology and Therapeutics Symposium Series. 2006 ; Vol. 2, No. 1. pp. 104-110.
@article{3e582dec32a74a49b11ae758b2dbd18c,
title = "Enhanced plasma ghrelin levels in patients with functional dyspepsia",
abstract = "Background: Ghrelin, growth-hormone-releasing peptide, has been reported to accelerate food intake and gastrointestinal motility. Aim: The present study was designed to investigate the plasma ghrelin levels in patients with functional dyspepsia (FD). Patients and Methods: Ninety-seven patients, who showed no evidence of peptic ulcer disease or gastrointestinal cancer on upper gastrointestinal endoscopy, were recruited. Seventeen patients who had no gastrointestinal symptoms were recruited as controls. Forty-seven patients were diagnosed to be suffering from FD, based on the Rome II criteria. The FD patients were further subdivided into those with ulcer-like FD, dysmotility-like FD and non-specific-type FD, based on their Gastrointestinal Symptom Rating Scale (GSRS) scores. Fourteen patients were categorized as having gastro-oesophageal reflux disease, and 19 patients were excluded as having the irritable bowel syndrome, based on the GSRS. The plasma ghrelin levels were measured by radioimmunoassay. Results: The plasma ghrelin levels were significantly higher in FD patients, especially in those with dysmotility-like FD, as compared with those in controls. The plasma ghrelin levels were also correlated well with the indigestion scores. Conclusion: Plasma ghrelin levels are significantly higher in patients with dysmotility-like FD, suggesting that this parameter could become useful as a novel supportive marker for the diagnosis of FD.",
author = "T. Nishizawa and Hidekazu Suzuki and Y. Nomoto and Tatsuhiro Masaoka and H. Hosoda and M. Mori and T. Ohara and T. Morishita and K. Kangawa and T. Hibi",
year = "2006",
month = "7",
doi = "10.1111/j.1746-6342.2006.00032.x",
language = "English",
volume = "2",
pages = "104--110",
journal = "Alimentary Pharmacology and Therapeutics Symposium Series",
issn = "1746-6334",
number = "1",

}

TY - JOUR

T1 - Enhanced plasma ghrelin levels in patients with functional dyspepsia

AU - Nishizawa, T.

AU - Suzuki, Hidekazu

AU - Nomoto, Y.

AU - Masaoka, Tatsuhiro

AU - Hosoda, H.

AU - Mori, M.

AU - Ohara, T.

AU - Morishita, T.

AU - Kangawa, K.

AU - Hibi, T.

PY - 2006/7

Y1 - 2006/7

N2 - Background: Ghrelin, growth-hormone-releasing peptide, has been reported to accelerate food intake and gastrointestinal motility. Aim: The present study was designed to investigate the plasma ghrelin levels in patients with functional dyspepsia (FD). Patients and Methods: Ninety-seven patients, who showed no evidence of peptic ulcer disease or gastrointestinal cancer on upper gastrointestinal endoscopy, were recruited. Seventeen patients who had no gastrointestinal symptoms were recruited as controls. Forty-seven patients were diagnosed to be suffering from FD, based on the Rome II criteria. The FD patients were further subdivided into those with ulcer-like FD, dysmotility-like FD and non-specific-type FD, based on their Gastrointestinal Symptom Rating Scale (GSRS) scores. Fourteen patients were categorized as having gastro-oesophageal reflux disease, and 19 patients were excluded as having the irritable bowel syndrome, based on the GSRS. The plasma ghrelin levels were measured by radioimmunoassay. Results: The plasma ghrelin levels were significantly higher in FD patients, especially in those with dysmotility-like FD, as compared with those in controls. The plasma ghrelin levels were also correlated well with the indigestion scores. Conclusion: Plasma ghrelin levels are significantly higher in patients with dysmotility-like FD, suggesting that this parameter could become useful as a novel supportive marker for the diagnosis of FD.

AB - Background: Ghrelin, growth-hormone-releasing peptide, has been reported to accelerate food intake and gastrointestinal motility. Aim: The present study was designed to investigate the plasma ghrelin levels in patients with functional dyspepsia (FD). Patients and Methods: Ninety-seven patients, who showed no evidence of peptic ulcer disease or gastrointestinal cancer on upper gastrointestinal endoscopy, were recruited. Seventeen patients who had no gastrointestinal symptoms were recruited as controls. Forty-seven patients were diagnosed to be suffering from FD, based on the Rome II criteria. The FD patients were further subdivided into those with ulcer-like FD, dysmotility-like FD and non-specific-type FD, based on their Gastrointestinal Symptom Rating Scale (GSRS) scores. Fourteen patients were categorized as having gastro-oesophageal reflux disease, and 19 patients were excluded as having the irritable bowel syndrome, based on the GSRS. The plasma ghrelin levels were measured by radioimmunoassay. Results: The plasma ghrelin levels were significantly higher in FD patients, especially in those with dysmotility-like FD, as compared with those in controls. The plasma ghrelin levels were also correlated well with the indigestion scores. Conclusion: Plasma ghrelin levels are significantly higher in patients with dysmotility-like FD, suggesting that this parameter could become useful as a novel supportive marker for the diagnosis of FD.

UR - http://www.scopus.com/inward/record.url?scp=33746559899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746559899&partnerID=8YFLogxK

U2 - 10.1111/j.1746-6342.2006.00032.x

DO - 10.1111/j.1746-6342.2006.00032.x

M3 - Article

AN - SCOPUS:33746559899

VL - 2

SP - 104

EP - 110

JO - Alimentary Pharmacology and Therapeutics Symposium Series

JF - Alimentary Pharmacology and Therapeutics Symposium Series

SN - 1746-6334

IS - 1

ER -